<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332512</url>
  </required_header>
  <id_info>
    <org_study_id>HR-APTN-Ⅲ-NSCLC-02</org_study_id>
    <nct_id>NCT02332512</nct_id>
  </id_info>
  <brief_title>Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)</brief_title>
  <acronym>ANSWER</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase III Trial of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)&#xD;
      tyrosine kinase inhibitor (TKI). The investigators have finished the preclinical,phase I and&#xD;
      phase II clinical studies and found its promising anti-tumor activity and tolerable&#xD;
      toxicities. A disease-control rate of 61.1% and a mPFS of 4.7 months were showed in apatinib&#xD;
      phase II study in patients with NSCLC.&#xD;
&#xD;
      The study aims to compare the efficacy and safety of apatinib to placebo in advanced&#xD;
      non-squamous non-small cell lung cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival（OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival (OS) was defined as the time from date of randomization to date of death due to any cause.The date the patient was recorded alive of last follow-up.Median time results from unstratified Kaplan-Meier estimates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR was defined as the proportion of patients whose best response was Complete Response [CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target)] or Partial Response [PR: at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD] over the whole duration of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>24 months</time_frame>
    <description>DoR was defined as the time from documentation of tumor response to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>DCR was defined as the proportion of patients whose best response was CR or PR or Stable Disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in European Organization for Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ-C30)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">417</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib tablet administered orally, 750 mg,once daily until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet administered orally, once a day until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects &gt;/= 18 years and &lt;/=70 years of age at the time of Informed Consent.&#xD;
&#xD;
          2. Advanced relapsed or refractory predominantly NSCLC with documented wild-type EGFR.&#xD;
&#xD;
          3. At least one measurable lesion according to RECIST 1.1.&#xD;
&#xD;
          4. Failure of second line of chemotherapy.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          6. Patients must have recovered from any AEs of prior treatments before randamization.&#xD;
&#xD;
          7. Adequate bone marrow,liver and renal function as assessed by the following laboratory&#xD;
             tests conducted within 1 week before randomization. HB ≥ 90g/L; ANC≥1.5×10E+9/L;&#xD;
             PLT≥80×10E+9/L; ALT and AST &lt; 2.5×ULN; TBIL ≤1.25×ULN; Cr ≤1.25×ULN;CL&gt;45 ml/min.&#xD;
&#xD;
          8. Life expectancy of at least three months.&#xD;
&#xD;
          9. Written informed consent and the willingness and ability to comply with all aspects of&#xD;
             the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of types of small-cell, squamous-cell, adeno-squamous-cell lung cancer.&#xD;
&#xD;
          2. Pregnant or breast-feeding women.&#xD;
&#xD;
          3. Suffered from grade II or above myocardial ischemia or myocardial infarction,&#xD;
             uncontrolled arrhythmias (including QT interval male ≥ 450 ms, female≥ 470 ms).Severe&#xD;
             or uncontrolled systemic disease such as clinically significant hypertension(systolic&#xD;
             pressure &gt;/= 140 mm Hg and/or diastolic pressure &gt;/= 90 mm Hg), and Grade III-IV&#xD;
             cardiac insufficiency, according to NYHA criteria or echocardiography check: LVEF&lt;50%.&#xD;
&#xD;
          4. Factors to affect oral administration(inability to swallow tablets,GI tract resection,&#xD;
             chronic bacillary diarrhea and intestinal obstruction).&#xD;
&#xD;
          5. Coagulation disfunction,hemorrhagic tendency or receiving anticoagulant therapy&gt;/=&#xD;
             CTCAE 2 pneumorrhagia or &gt;/= CTCAE 3 hemorrhage in other organs within 4 weeks.&#xD;
&#xD;
          6. Bone fracture or wounds that was not cured.&#xD;
&#xD;
          7. Arterial thrombus or phlebothrombosis within 12 months and taking anticoagulant&#xD;
             agents.&#xD;
&#xD;
          8. Mental diseases and psychotropic substances abuse.&#xD;
&#xD;
          9. Previous treatment with an trial agent within 4 weeks&#xD;
&#xD;
         10. Previous treatment with VEGFR,platelet derived growth factor receptor(PDGFR) TKIs.&#xD;
&#xD;
         11. Proteinuria ≥ (++) or 24 hours total urine protein &gt; 1.0 g.&#xD;
&#xD;
         12. Other coexisting malignant disease (except basal-cell carcinoma and carcinoma in situ&#xD;
             of uterine cervix).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shunjiang Yu</last_name>
    <phone>+86-021-68868768</phone>
    <email>yushunjiang@hrs.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medical Oncology, Cancer Center, Sun Yet-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, MD</last_name>
      <phone>862087343088</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caicun Zhou, M. D.</last_name>
      <email>caicunzhou@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 4, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-squamous non-small cell lung cancer</keyword>
  <keyword>Wild-type EGFR</keyword>
  <keyword>3rd/4th line treatment</keyword>
  <keyword>apatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

